Last reviewed 2026-04-20 · How we verify

MDX-010

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Diarrhoea
• Fatigue
• Nausea
• Pruritus
• Decreased appetite
• Rash
• Anaemia
• Vomiting
• Constipation
• Headache
• Pyrexia
• Cough

Key clinical trials

• Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
• Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (PHASE1)
• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
• Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (PHASE1, PHASE2)
• A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MDX-010 CI brief — competitive landscape report
• MDX-010 updates RSS · CI watch RSS
• National Cancer Institute (NCI) portfolio CI